Assertio Holdings, Inc. (ASRT)

1,0100 +0,0888 (+9,64 %) À la clôture : 04:00PM EDT

Assertio Holdings, Inc.

100 South Saunders Road
Suite 300
Lake Forest, IL 60045
United States
224 419 7106
https://www.assertiotx.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 53

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Ms. Heather L. Mason	Interim CEO & Director	92,5k	S.O.	1960
Mr. Ajay Patel	Senior VP & CFO	538,79k	S.O.	1984
Mr. Paul Schwichtenberg	Senior Vice President & Chief Commercial Officer	573,65k	S.O.	1971
Mr. Bill Iskos	Senior Vice President of Operations	S.O.	S.O.	S.O.
Ms. Molly Dir	Senior Vice President of HR & Administration ?	S.O.	S.O.	S.O.
Mr. Sam Schlessinger	Senior VP & General Counsel	S.O.	S.O.	1982
Dr. Howard J. Franklin M.B.A., M.D.	Senior Vice President of Medical	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Assertio Holdings, Inc. en date du 1 mai 2024 est 2. Les scores principaux sont Audit : 7; Société : 4; Droits des actionnaires : 1; Compensation : 3.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.